Literature DB >> 12618211

Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate.

Markus Fueller1, De An Wang, Gabor Tigyi, Wolfgang Siess.   

Abstract

Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are serum-borne lipid mediators with potential proinflammatory and atherogenic properties. We studied the effects of LPA and S1P on [Ca(2+)](i), a second messenger of cellular activation, in human monocytic Mono Mac 6 (MM6) cells. LPA and S1P induced [Ca(2+)](i) transients with EC(50) values of 47 and 340 nM, respectively. Ca(2+) signals evoked by LPA and S1P originated mainly from the stimulation of Ca(2+) entry, were blocked by the phospholipase C inhibitor U73122, and were inhibited by pertussis toxin. The LPA(1) and LPA(3) receptor antagonist dioctylglycerol pyrophosphate inhibited the LPA-induced Ca(2+) signal. Notably, serum and minimally modified LDL (mm-LDL) evoked [Ca(2+)](i) increases that were mediated entirely through activation of LPA receptors. Reverse transcriptase polymerase chain reaction (RT-PCR) analysis showed the presence of the LPA and S1P receptor subtypes LPA(1), LPA(2,) S1P(1), S1P(2), S1P(4) in MM6 cells, human monocytes and macrophages. Together these results indicate that LPA, mm-LDL and serum induce via activation of the LPA(1) receptor a G(i)/phospholipase C/Ca(2+) signalling pathway in monocytes. Our study is the first report showing the receptor-mediated activation of human monocytic cells by low nanomolar concentrations of LPA and S1P, and suggests a role of these lipid mediators in inflammation and atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618211     DOI: 10.1016/s0898-6568(02)00117-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  33 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

4.  Possible role of lysophosphatidic acid in rat model of hypoxic pulmonary vascular remodeling.

Authors:  Vadim Shlyonsky; Robert Naeije; Frédérique Mies
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

5.  Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate.

Authors:  Fiorentina Roviezzo; Francesco Del Galdo; Gianfranco Abbate; Mariarosaria Bucci; Bruno D'Agostino; Edson Antunes; Gianfranco De Dominicis; Luca Parente; Francesco Rossi; Giuseppe Cirino; Raffaele De Palma
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-14       Impact factor: 11.205

6.  Sphingosine kinase regulates oxidized low density lipoprotein-mediated calcium oscillations and macrophage survival.

Authors:  Johnny H Chen; Maziar Riazy; Shih Wei Wang; Jiazhen Minnie Dai; Vincent Duronio; Urs P Steinbrecher
Journal:  J Lipid Res       Date:  2009-11-05       Impact factor: 5.922

Review 7.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 8.  The alliance of sphingosine-1-phosphate and its receptors in immunity.

Authors:  Juan Rivera; Richard L Proia; Ana Olivera
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

9.  Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages.

Authors:  Samar M Hammad; Heather G Crellin; Bill X Wu; Jessica Melton; Viviana Anelli; Lina M Obeid
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-11-24       Impact factor: 3.072

10.  Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist.

Authors:  Scott E Wenderfer; Stanislaw M Stepkowski; Michael C Braun
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.